FDA Approves First mRNA-Based Flu Vaccine for Adults 50 and Older
The U.S. Food and Drug Administration has approved MFLUSIVA, also known as mFlusiva, the first mRNA-based seasonal influenza vaccine approved in the United States. Manufactured by ModernaTX, Inc., it is authorized for adults 50 and older ahead of the 2026–2027 flu season, according to the FDA.
The decision creates another option for a group that faces a higher risk of serious flu complications. In its late-stage study of roughly 40,000 adults, Moderna reported that mFlusiva resulted in about 27% fewer influenza cases than a standard-dose flu vaccine among adults ages 50 to 64, as reported by the Associated Press.
For adults 50 through 64, the FDA granted traditional approval. For adults 65 and older, the agency granted accelerated approval based primarily on immune-response data. Moderna must complete an additional study to confirm clinical benefit in that older age group.
Like other vaccines, mFlusiva can cause temporary reactions. Reported effects include injection-site pain, headache, fatigue, fever and muscle aches. The FDA and Moderna reported no major new safety concerns in studies involving more than 43,000 participants.
If you are eligible, ask your doctor or pharmacist whether mFlusiva is available and appropriate for you. Discuss allergies, existing health conditions and how it may fit with your broader seasonal vaccination plan. Availability may vary by location, so calling ahead could save a trip.
A practical neighborhood step is to check on older relatives, friends and neighbors who may need help arranging transportation or appointments. What questions do you have about the new vaccine; or about preparing your household for flu season?
This article is for general information and is not a substitute for medical advice.
Sources: FDA product information; FDA clinical review; Associated Press.
